AI Article Synopsis
Article Abstract
The authors administered procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, lomustine), and vincristine (PCV) to 86 patients with recurrent glioblastoma. There were three partial responses, but no complete responses. Median progression-free survival was 17.1 weeks and progression-free survival at 6 months was 38.4%. World Health Organization grade III/IV hematologic toxicity was common (25.6%), but nonhematologic toxicity was mild.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1212/01.wnl.0000197792.73656.c2 | DOI Listing |
Publication Analysis
Top Keywords
recurrent glioblastoma
8
progression-free survival
8
pcv chemotherapy
4
chemotherapy recurrent
4
glioblastoma authors
4
authors administered
4
administered procarbazine
4
procarbazine 1-2-chloroethyl-3-cyclohexyl-1-nitrosourea
4
1-2-chloroethyl-3-cyclohexyl-1-nitrosourea ccnu
4
ccnu lomustine
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!